Tradename | Company | Number | Date | Products |
---|---|---|---|---|
MARQIBO KIT | Acrotech Biopharma | N-202497 DISCN | 2012-08-09 | 1 products, RLD |
ONCOVIN | Eli Lilly | N-014103 DISCN | 1982-01-01 | 3 products, RLD |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 52 | 88 | 41 | 22 | 14 | 193 |
Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 37 | 89 | 38 | 5 | 3 | 149 |
Non-hodgkin lymphoma | D008228 | — | C85.9 | 25 | 38 | 15 | 4 | 6 | 79 |
Follicular lymphoma | D008224 | — | C82 | 16 | 19 | 16 | 2 | 1 | 45 |
T-cell lymphoma peripheral | D016411 | — | — | 12 | 20 | 7 | 2 | 1 | 37 |
Mantle-cell lymphoma | D020522 | — | C83.1 | 10 | 23 | 8 | 1 | — | 35 |
Burkitt lymphoma | D002051 | — | C83.7 | 12 | 14 | — | 2 | — | 25 |
B-cell lymphoma | D016393 | — | — | 11 | 10 | 4 | 1 | — | 22 |
Retinoblastoma | D012175 | — | — | 3 | 10 | 6 | 1 | 2 | 21 |
Neoplasms | D009369 | — | C80 | 11 | 5 | 2 | 1 | 2 | 20 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Lymphoma | D008223 | — | C85.9 | 24 | 108 | 55 | — | 15 | 191 |
Leukemia | D007938 | — | C95 | 10 | 43 | 32 | — | 8 | 86 |
Neuroblastoma | D009447 | EFO_0000621 | — | 15 | 20 | 16 | — | 4 | 55 |
Central nervous system neoplasms | D016543 | — | — | 7 | 20 | 13 | — | 5 | 43 |
Hodgkin disease | D006689 | — | C81 | 6 | 22 | 15 | — | 2 | 41 |
Sarcoma | D012509 | — | — | 5 | 19 | 11 | — | 3 | 38 |
Ewing sarcoma | D012512 | EFO_0000173 | — | 4 | 15 | 2 | — | 3 | 22 |
Multiple myeloma | D009101 | — | C90.0 | 4 | 10 | 7 | — | 1 | 20 |
Rhabdomyosarcoma | D012208 | — | — | 5 | 11 | 6 | — | 1 | 19 |
Brain neoplasms | D001932 | EFO_0003833 | C71 | 5 | 8 | 4 | — | 2 | 18 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Myelodysplastic syndromes | D009190 | — | D46 | 6 | 4 | — | — | — | 7 |
Precursor t-cell lymphoblastic leukemia-lymphoma | D054218 | — | — | 4 | 5 | — | — | — | 7 |
Biphenotypic leukemia acute | D015456 | — | C95.0 | 3 | 5 | — | — | — | 7 |
Aids-related lymphoma | D016483 | EFO_1001365 | — | 1 | 5 | — | — | — | 6 |
Reactive arthritis | D016918 | EFO_0007460 | M02.3 | 1 | 5 | — | — | — | 5 |
Plasmablastic lymphoma | D000069293 | — | C83.3 | 4 | 3 | — | — | — | 5 |
Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 2 | 3 | — | — | — | 5 |
Adult t-cell leukemia-lymphoma | D015459 | — | C91.5 | 3 | 2 | — | — | — | 4 |
B-cell lymphoma marginal zone | D018442 | — | C88.4 | 2 | 3 | — | — | — | 4 |
Lymphoid leukemia | D007945 | — | C91 | 2 | 1 | — | — | — | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Recurrence | D012008 | — | — | 2 | — | — | — | — | 2 |
Pinealoma | D010871 | — | — | 1 | — | — | — | 1 | 2 |
Hypersensitivity | D006967 | HP_0012393 | T78.40 | 1 | — | — | — | — | 1 |
Germ cell and embryonal neoplasms | D009373 | — | — | 1 | — | — | — | — | 1 |
Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | — | — | — | — | 1 |
Deltaretrovirus infections | D006800 | EFO_1001303 | — | 1 | — | — | — | — | 1 |
Syndrome | D013577 | — | — | 1 | — | — | — | — | 1 |
Composite lymphoma | D058617 | — | — | 1 | — | — | — | — | 1 |
Hematologic diseases | D006402 | EFO_0005803 | D75.9 | 1 | — | — | — | — | 1 |
Melanoma | D008545 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Vomiting | D014839 | HP_0002013 | R11.1 | — | — | — | — | 2 | 2 |
Constipation | D003248 | HP_0002019 | K59.0 | — | — | — | — | 2 | 2 |
Non-small-cell lung carcinoma | D002289 | — | — | — | — | — | — | 1 | 1 |
Nausea | D009325 | HP_0002018 | R11.0 | — | — | — | — | 1 | 1 |
Ataxia telangiectasia | D001260 | Orphanet_100 | G11.3 | — | — | — | — | 1 | 1 |
Ototoxicity | D000081015 | — | — | — | — | — | — | 1 | 1 |
Nerve degeneration | D009410 | HP_0002180 | — | — | — | — | — | 1 | 1 |
Neural conduction | D009431 | — | — | — | — | — | — | 1 | 1 |
Pituitary neoplasms | D010911 | — | — | — | — | — | — | 1 | 1 |
Sertoli-leydig cell tumor | D018310 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Vincristine sulfate |
INN | vincristine |
Description | Vincristine is a vinca alkaloid with formula C46H56N4O10 found in the Madagascar periwinkle, Catharanthus roseus. It is used (commonly as the corresponding sulfate salt)as a chemotherapy drug for the treatment of leukaemia, lymphoma, myeloma, breast cancer and head and neck cancer. It has a role as a tubulin modulator, a microtubule-destabilising agent, a plant metabolite, an antineoplastic agent and a drug. It is a methyl ester, an acetate ester, a tertiary alcohol, a member of formamides, an organic heteropentacyclic compound, an organic heterotetracyclic compound, a tertiary amino compound and a vinca alkaloid. It is a conjugate base of a vincristine(2+). It derives from a hydride of a vincaleukoblastine. |
Classification | Small molecule |
Drug class | vinca alkaloids |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O |
PDB | — |
CAS-ID | 2068-78-2 |
RxCUI | — |
ChEMBL ID | CHEMBL501867 |
ChEBI ID | 79401 |
PubChem CID | 5978 |
DrugBank | DBSALT000314 |
UNII ID | 5J49Q6B70F (ChemIDplus, GSRS) |